US2021069335A1PendingUtilityA1

Compositions, gels and foams with rheology modulators and uses thereof

78
Assignee: FOAMIX PHARMACEUTICALS LTDPriority: Oct 2, 2009Filed: Oct 1, 2020Published: Mar 11, 2021
Est. expiryOct 2, 2029(~3.2 yrs left)· nominal 20-yr term from priority
Inventors:Dov TamarkinElana GazalYohan HazotDavid SchuzIrakliy Papiashvili
A61K 31/192A61K 47/44A61K 47/12A61K 47/10A61K 31/593A61Q 19/00A61P 17/16A61K 8/342A61K 31/65A61P 5/00A61P 31/22A61Q 19/10A61P 31/12A61P 7/10A61K 9/0014A61P 35/00A61P 17/12A61K 31/57A61P 31/18A61P 17/02A61P 17/06A61K 31/573A61P 29/00A61K 47/02A61P 25/20A61Q 17/04A61P 1/00A61P 33/14A61K 2800/33A61K 47/06A61P 39/06A61P 37/06A61P 31/10A61K 31/4164A61K 9/122A61P 23/00A61K 9/0048A61P 27/06A61P 9/00A61K 31/137A61K 8/361A61P 9/08A61P 17/14A61K 8/31A61P 27/02A61P 31/20A61P 11/00A61P 17/10A61K 2800/31A61P 17/04A61K 47/24A61P 19/02A61P 17/00A61P 31/14A61P 17/08A61P 15/00A61K 9/12A61K 9/124A61P 37/08A61P 37/04A61P 37/02A61P 25/00A61P 31/00A61P 15/02A61P 33/10A61P 37/00A61P 33/00A61P 25/24A61P 31/04A61K 45/06
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.APP

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A foam composition comprising:
 a) a combination of at least one fatty alcohol and at least one wax; or a combination of at least one fatty alcohol, at least one fatty acid, and at least one wax;   b) at least one hydrophobic solvent;   c) a minocycline at a concentration between about 0.2% and about 20% by weight of the composition; and   d) a retinoid;   wherein the composition is free of surfactant;   wherein the composition is essentially waterless; and   wherein the ratio of (1) fatty alcohol to wax or (2) fatty alcohol and fatty acid to wax is between about 1:3 and about 3:1.   
     
     
         3 . The composition of  claim 2 , wherein the minocycline is present in a free base form, a hydrate form, a salt form, or a complex form. 
     
     
         4 . The composition of  claim 2 , wherein the foam composition further comprises a tetracycline, an oxytetracycline, a demeclocycline, a doxycycline, a lymecycline, a meclocycline, a methacycline, a rolitetracycline, a chlorotetracycline, a tigecycline, or a mixture of two or more thereof. 
     
     
         5 . The composition of  claim 2 , wherein the concentration of the minocycline is between about 1% and about 10% by weight of the composition. 
     
     
         6 . The composition of  claim 2 , wherein the concentration of the minocycline is between about 1% and about 4% by weight of the composition. 
     
     
         7 . The composition of  claim 2 , wherein the concentration of the minocycline is about 3% by weight of the composition. 
     
     
         8 . The composition of  claim 2 , wherein the concentration of the minocycline is about 1.5% by weight of the composition. 
     
     
         9 . The composition of  claim 2 , wherein the at least one fatty alcohol comprises 14 carbon atoms in its backbone. 
     
     
         10 . The composition of  claim 2 , wherein the fatty alcohol comprises stearyl alcohol, cetostearyl alcohol, behenyl alcohol, and/or myristyl alcohol. 
     
     
         11 . The composition of  claim 2 , wherein the at least one fatty alcohol is present at a concentration from about 0.1% to about 20% by weight of the composition. 
     
     
         12 . The composition of  claim 2 , wherein the at least one wax and/or the at least one fatty acid is present at a concentration from about 0.1% to about 20% by weight of the composition. 
     
     
         13 . The composition of  claim 2 , wherein the hydrophobic solvent comprises soybean oil, coconut oil, cyclomethicone, and/or mineral oil. 
     
     
         14 . The composition of  claim 2 , wherein the hydrophobic solvent is present at a concentration from about 60% to about 95% by weight of the composition. 
     
     
         15 . The composition of  claim 2 , wherein the foam composition further comprises a silicon dioxide. 
     
     
         16 . The composition of  claim 2 , wherein the foam composition further comprises a benzoyl peroxide. 
     
     
         17 . The composition of  claim 2 , wherein the wax comprises a mixture of beeswax and/or hydrogenated castor oil. 
     
     
         18 . The composition of  claim 2 , wherein the retinoid comprises tazarotene, adapalene, and/or isotretinoin. 
     
     
         19 . The composition of  claim 2 , wherein the retinoid comprises a therapeutically effective amount of adapalene. 
     
     
         20 . The composition of  claim 2 , wherein the wax comprises beeswax and hydrogenated castor oil. 
     
     
         21 . The composition of  claim 20 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 5:1 to about 1:1. 
     
     
         22 . The composition of  claim 20 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 2:1 to about 1:1. 
     
     
         23 . The composition of  claim 20 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 1:1. 
     
     
         24 . The composition of  claim 20 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 4:3. 
     
     
         25 . A foam composition comprising:
 a) a combination of at least one fatty alcohol and at least one wax; or a combination of at least one fatty alcohol, at least one fatty acid, and at least one wax;   b) at least one hydrophobic solvent;   c) a minocycline at a concentration between about 0.2% and about 20% by weight of the composition; and   d) a retinoid;   wherein the composition is free of surfactant;   wherein the composition has a water activity (Aw) value of less than about 0.9; and   wherein the ratio of (1) fatty alcohol to wax or (2) fatty alcohol and fatty acid to wax is between about 1:3 and about 3:1   
     
     
         26 . The composition of  claim 25 , wherein the composition has an Aw value of less than about 0.5. 
     
     
         27 . The composition of  claim 25 , wherein the minocycline is present in a free base form, a hydrate form, a salt form, or a complex form. 
     
     
         28 . The composition of  claim 25 , wherein the foam composition further comprises a tetracycline, an oxytetracycline, a demeclocycline, a doxycycline, a lymecycline, a meclocycline, a methacycline, a rolitetracycline, a chlorotetracycline, a tigecycline, or a mixture of two or more thereof. 
     
     
         29 . The composition of  claim 25 , wherein the concentration of the minocycline is between about 1% and about 10% by weight of the composition. 
     
     
         30 . The composition of  claim 25 , wherein the concentration of the minocycline is between about 1% and about 4% by weight of the composition. 
     
     
         31 . The composition of  claim 25 , wherein the concentration of the minocycline is about 3% by weight of the composition. 
     
     
         32 . The composition of  claim 25 , wherein the concentration of the minocycline is about 1.5% by weight of the composition. 
     
     
         33 . The composition of  claim 25 , wherein the at least one fatty alcohol comprises 14 carbon atoms in its backbone. 
     
     
         34 . The composition of  claim 25 , wherein the fatty alcohol comprises stearyl alcohol, cetostearyl alcohol, behenyl alcohol, and/or myristyl alcohol. 
     
     
         35 . The composition of  claim 25 , wherein the at least one fatty alcohol is present at a concentration from about 0.1% to about 20% by weight of the composition. 
     
     
         36 . The composition of  claim 25 , wherein the at least one wax and/or the at least one fatty acid is present at a concentration from about 0.1% to about 20% by weight of the composition. 
     
     
         37 . The composition of  claim 25 , wherein the hydrophobic solvent comprises soybean oil, coconut oil, cyclomethicone, and/or mineral oil. 
     
     
         38 . The composition of  claim 25 , wherein the hydrophobic solvent is present at a concentration from about 60% to about 95% by weight of the composition. 
     
     
         39 . The composition of  claim 25 , wherein the foam composition further comprises a silicon dioxide. 
     
     
         40 . The composition of  claim 25 , wherein the foam composition further comprises a benzoyl peroxide. 
     
     
         41 . The composition of  claim 25 , wherein the wax comprises a mixture of beeswax and/or hydrogenated castor oil. 
     
     
         42 . The composition of  claim 25 , wherein the retinoid comprises tazarotene, adapalene, and/or isotretinoin. 
     
     
         43 . The composition of  claim 25 , wherein the retinoid comprises a therapeutically effective amount of adapalene. 
     
     
         44 . The composition of  claim 25 , wherein the wax comprises beeswax and hydrogenated castor oil. 
     
     
         45 . The composition of  claim 44 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 5:1 to about 1:1. 
     
     
         46 . The composition of  claim 44 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 2:1 to about 1:1. 
     
     
         47 . The composition of  claim 44 , wherein the beeswax and hydrogenated castor oil are at a ratio of about 1:1.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.